These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
362 related articles for article (PubMed ID: 23791828)
1. Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapies. Ross JS; Ali SM; Wang K; Palmer G; Yelensky R; Lipson D; Miller VA; Zajchowski D; Shawver LK; Stephens PJ Gynecol Oncol; 2013 Sep; 130(3):554-9. PubMed ID: 23791828 [TBL] [Abstract][Full Text] [Related]
2. Comprehensive genomic profiling of relapsed and metastatic adenoid cystic carcinomas by next-generation sequencing reveals potential new routes to targeted therapies. Ross JS; Wang K; Rand JV; Sheehan CE; Jennings TA; Al-Rohil RN; Otto GA; Curran JC; Palmer G; Downing SR; Yelensky R; Lipson D; Balasubramanian S; Garcia L; Mahoney K; Ali SM; Miller VA; Stephens PJ Am J Surg Pathol; 2014 Feb; 38(2):235-8. PubMed ID: 24418857 [TBL] [Abstract][Full Text] [Related]
3. Next-Generation Sequencing Reveals Pathway Activations and New Routes to Targeted Therapies in Cutaneous Metastatic Melanoma. Carlson JA; Caldeira Xavier JC; Tarasen A; Sheehan CE; Otto G; Miller VA; Stephens PJ; Elvin JA; Vergilio JA; Suh J; Gay LM; Ross JS Am J Dermatopathol; 2017 Jan; 39(1):1-13. PubMed ID: 28045747 [TBL] [Abstract][Full Text] [Related]
4. Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling study. Ross JS; Gay LM; Nozad S; Wang K; Ali SM; Boguniewicz A; Khaira D; Johnson A; Elvin JA; Vergilio JA; Suh J; Miller VA; Stephens PJ Breast Cancer Res Treat; 2016 Jan; 155(2):405-13. PubMed ID: 26762307 [TBL] [Abstract][Full Text] [Related]
5. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms. Mackenzie R; Kommoss S; Winterhoff BJ; Kipp BR; Garcia JJ; Voss J; Halling K; Karnezis A; Senz J; Yang W; Prigge ES; Reuschenbach M; Doeberitz MV; Gilks BC; Huntsman DG; Bakkum-Gamez J; McAlpine JN; Anglesio MS BMC Cancer; 2015 May; 15():415. PubMed ID: 25986173 [TBL] [Abstract][Full Text] [Related]
6. Genomic profiling of advanced-stage, metaplastic breast carcinoma by next-generation sequencing reveals frequent, targetable genomic abnormalities and potential new treatment options. Ross JS; Badve S; Wang K; Sheehan CE; Boguniewicz AB; Otto GA; Yelensky R; Lipson D; Ali S; Morosini D; Chliemlecki J; Elvin JA; Miller VA; Stephens PJ Arch Pathol Lab Med; 2015 May; 139(5):642-9. PubMed ID: 25927147 [TBL] [Abstract][Full Text] [Related]
7. Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials. Meagher NS; Schuster K; Voss A; Budden T; Pang CNI; deFazio A; Ramus SJ; Friedlander ML Gynecol Oncol; 2018 Sep; 150(3):527-533. PubMed ID: 30054102 [TBL] [Abstract][Full Text] [Related]
8. Relapsed classic E-cadherin (CDH1)-mutated invasive lobular breast cancer shows a high frequency of HER2 (ERBB2) gene mutations. Ross JS; Wang K; Sheehan CE; Boguniewicz AB; Otto G; Downing SR; Sun J; He J; Curran JA; Ali S; Yelensky R; Lipson D; Palmer G; Miller VA; Stephens PJ Clin Cancer Res; 2013 May; 19(10):2668-76. PubMed ID: 23575477 [TBL] [Abstract][Full Text] [Related]
10. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Beltran H; Yelensky R; Frampton GM; Park K; Downing SR; MacDonald TY; Jarosz M; Lipson D; Tagawa ST; Nanus DM; Stephens PJ; Mosquera JM; Cronin MT; Rubin MA Eur Urol; 2013 May; 63(5):920-6. PubMed ID: 22981675 [TBL] [Abstract][Full Text] [Related]
11. Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations. Ross JS; Ali SM; Wang K; Khaira D; Palma NA; Chmielecki J; Palmer GA; Morosini D; Elvin JA; Fernandez SV; Miller VA; Stephens PJ; Cristofanilli M Breast Cancer Res Treat; 2015 Nov; 154(1):155-62. PubMed ID: 26458824 [TBL] [Abstract][Full Text] [Related]
13. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis. Dehari R; Kurman RJ; Logani S; Shih IeM Am J Surg Pathol; 2007 Jul; 31(7):1007-12. PubMed ID: 17592266 [TBL] [Abstract][Full Text] [Related]
14. Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy. Ross JS; Wang K; Al-Rohil RN; Nazeer T; Sheehan CE; Otto GA; He J; Palmer G; Yelensky R; Lipson D; Ali S; Balasubramanian S; Curran JA; Garcia L; Mahoney K; Downing SR; Hawryluk M; Miller VA; Stephens PJ Mod Pathol; 2014 Feb; 27(2):271-80. PubMed ID: 23887298 [TBL] [Abstract][Full Text] [Related]
15. Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches. Drilon A; Wang L; Arcila ME; Balasubramanian S; Greenbowe JR; Ross JS; Stephens P; Lipson D; Miller VA; Kris MG; Ladanyi M; Rizvi NA Clin Cancer Res; 2015 Aug; 21(16):3631-9. PubMed ID: 25567908 [TBL] [Abstract][Full Text] [Related]
16. Clinical next-generation sequencing successfully applied to fine-needle aspirations of pulmonary and pancreatic neoplasms. Young G; Wang K; He J; Otto G; Hawryluk M; Zwirco Z; Brennan T; Nahas M; Donahue A; Yelensky R; Lipson D; Sheehan CE; Boguniewicz AB; Stephens PJ; Miller VA; Ross JS Cancer Cytopathol; 2013 Dec; 121(12):688-94. PubMed ID: 23893923 [TBL] [Abstract][Full Text] [Related]
17. A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice. Vasan N; Yelensky R; Wang K; Moulder S; Dzimitrowicz H; Avritscher R; Wang B; Wu Y; Cronin MT; Palmer G; Symmans WF; Miller VA; Stephens P; Pusztai L Oncologist; 2014 May; 19(5):453-8. PubMed ID: 24710307 [TBL] [Abstract][Full Text] [Related]
18. Distinct molecular profiles in Lynch syndrome-associated and sporadic ovarian carcinomas. Niskakoski A; Kaur S; Renkonen-Sinisalo L; Lassus H; Järvinen HJ; Mecklin JP; Bützow R; Peltomäki P Int J Cancer; 2013 Dec; 133(11):2596-608. PubMed ID: 23716351 [TBL] [Abstract][Full Text] [Related]
19. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC). Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301 [TBL] [Abstract][Full Text] [Related]
20. Comprehensive Genomic Profiling of Advanced Penile Carcinoma Suggests a High Frequency of Clinically Relevant Genomic Alterations. Ali SM; Pal SK; Wang K; Palma NA; Sanford E; Bailey M; He J; Elvin JA; Chmielecki J; Squillace R; Dow E; Morosini D; Buell J; Yelensky R; Lipson D; Frampton GM; Howley P; Ross JS; Stephens PJ; Miller VA Oncologist; 2016 Jan; 21(1):33-9. PubMed ID: 26670666 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]